secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-05-11T20:06:06+00:00
Accession:  0001159036-26-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q1 revenue up 42% to $377M; new $1B buyback program
------------------------------------------------------------

- Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).
- GAAP diluted EPS $1.22 (vs $0.93); Non-GAAP diluted EPS $1.60 (vs $1.11).
- New $1B share repurchase program through 2028; at least $400M expected in 2026.
- Reiterated 2026 guidance: revenue $1.71B-$1.81B, Non-GAAP EPS $7.75-$8.25.
- Collaborations: GSK (multiple oncology ENHANZE targets), argenx VYVGART Hytrulo FDA-approved for all gMG serotypes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/0001159036-26-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/halo-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer